Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Quantification of minimal disseminated disease by quantitative PCR and digital PCR for NPM-ALK as prognostic factor in children with anaplastic large cell lymphoma.

Damm-Welk C, Kutscher N, Zimmermann M, Attarbaschi A, Schieferstein J, Knörr F, Oschlies I, Klapper W, Woessmann W.

Haematologica. 2019 Oct 24. pii: haematol.2019.232314. doi: 10.3324/haematol.2019.232314. [Epub ahead of print]

2.

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma.

Singh VK, Werner S, Schwalm S, Lennerz V, Ruf S, Stadler S, Hackstein H, Reiter A, Wölfel T, Damm-Welk C, Woessmann W.

Oncoimmunology. 2019 Jun 26;8(9):e1625688. doi: 10.1080/2162402X.2019.1625688. eCollection 2019.

3.

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

Pfeifer H, Cazzaniga G, van der Velden VHJ, Cayuela JM, Schäfer B, Spinelli O, Akiki S, Avigad S, Bendit I, Borg K, Cavé H, Elia L, Reshmi SC, Gerrard G, Hayette S, Hermanson M, Juh A, Jurcek T, Chillón MC, Homburg C, Martinelli G, Kairisto V, Lange T, Lion T, Mueller MC, Pane F, Rai L, Damm-Welk C, Sacha T, Schnittger S, Touloumenidou T, Valerhaugen H, Vandenberghe P, Zuna J, Serve H, Herrmann E, Markovic S, Dongen JJMV, Ottmann OG.

Leukemia. 2019 Aug;33(8):1910-1922. doi: 10.1038/s41375-019-0413-0. Epub 2019 Mar 11.

PMID:
30858550
4.

Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma.

Knörr F, Weber S, Singh VK, Pulford K, Reiter A, Woessmann W, Damm-Welk C.

Clin Immunol. 2018 Oct;195:77-81. doi: 10.1016/j.clim.2018.07.008. Epub 2018 Aug 1.

PMID:
30077013
5.

Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma.

Krumbholz M, Woessmann W, Zierk J, Seniuk D, Ceppi P, Zimmermann M, Singh VK, Metzler M, Damm-Welk C.

Oncotarget. 2018 May 29;9(41):26543-26555. doi: 10.18632/oncotarget.25489. eCollection 2018 May 29.

6.

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma.

Stadler S, Singh VK, Knörr F, Damm-Welk C, Woessmann W.

Cancers (Basel). 2018 Apr 10;10(4). pii: E114. doi: 10.3390/cancers10040114. Review.

7.

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.

Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S.

Leukemia. 2018 Sep;32(9):1994-2007. doi: 10.1038/s41375-018-0045-9. Epub 2018 Mar 28.

8.

Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Knörr F, Damm-Welk C, Ruf S, Singh VK, Zimmermann M, Reiter A, Woessmann W.

Haematologica. 2018 Mar;103(3):477-485. doi: 10.3324/haematol.2017.177972. Epub 2017 Dec 14.

9.

Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma.

Mussolin L, Pillon M, Zimmermann M, Carraro E, Basso G, Knoerr F, Woessmann W, Damm-Welk C.

Br J Haematol. 2018 Sep;182(5):733-735. doi: 10.1111/bjh.14864. Epub 2017 Aug 31. No abstract available.

PMID:
28857122
10.

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK.

Damm-Welk C, Siddiqi F, Fischer M, Hero B, Narayanan V, Camidge DR, Harris M, Burke A, Lehrnbecher T, Pulford K, Oschlies I, Siebert R, Turner S, Woessmann W.

J Cancer. 2016 Jun 30;7(11):1383-7. doi: 10.7150/jca.15238. eCollection 2016.

11.

Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.

K Singh V, Werner S, Hackstein H, Lennerz V, Reiter A, Wölfel T, Damm-Welk C, Woessmann W.

Clin Exp Immunol. 2016 Oct;186(1):96-105. doi: 10.1111/cei.12842. Epub 2016 Aug 16.

12.

Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.

Burkhardt B, Yavuz D, Zimmermann M, Schieferstein J, Kabickova E, Attarbaschi A, Lisfeld J, Reiter A, Makarova O, Worch J, Bonn BR, Damm-Welk C.

Ann Hematol. 2016 Sep;95(9):1503-12. doi: 10.1007/s00277-016-2731-x. Epub 2016 Jul 4.

PMID:
27376362
13.

Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.

Minard-Colin V, Brugières L, Reiter A, Cairo MS, Gross TG, Woessmann W, Burkhardt B, Sandlund JT, Williams D, Pillon M, Horibe K, Auperin A, Le Deley MC, Zimmerman M, Perkins SL, Raphael M, Lamant L, Klapper W, Mussolin L, Poirel HA, Macintyre E, Damm-Welk C, Rosolen A, Patte C.

J Clin Oncol. 2015 Sep 20;33(27):2963-74. doi: 10.1200/JCO.2014.59.5827. Epub 2015 Aug 24. Review.

14.

Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.

Damm-Welk C, Pillon M, Woessmann W, Mussolin L.

Front Biosci (Schol Ed). 2015 Jun 1;7:205-16. Review.

PMID:
25961696
15.

Multiplex ligation-dependent probe amplification validates LOH6q analyses and enhances insight into chromosome 6q aberrations in pediatric T-cell lymphoblastic leukemia and lymphoma.

Rohde M, Bonn BR, Zimmermann M, Szczepanowski M, Damm-Welk C, Stanulla M, Burkhardt B.

Leuk Lymphoma. 2015 Jun;56(6):1884-7. doi: 10.3109/10428194.2014.976820. Epub 2014 Nov 19. No abstract available.

PMID:
25330441
16.

Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols.

Rohde M, Richter J, Schlesner M, Betts MJ, Claviez A, Bonn BR, Zimmermann M, Damm-Welk C, Russell RB, Borkhardt A, Eils R, Hoell JI, Szczepanowski M, Oschlies I, Klapper W, Burkhardt B, Siebert R; German ICGC MMML-Seq-Project; NHL-BFM Study Group.

Genes Chromosomes Cancer. 2014 Nov;53(11):911-6. doi: 10.1002/gcc.22202. Epub 2014 Jul 8.

PMID:
25044415
17.

A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.

Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, Pienkowska-Grela B, Adam P, Burkhardt B, Claviez A, Damm-Welk C, Drexler HG, Hummel M, Jaffe ES, Küppers R, Lefebvre C, Lisfeld J, Löffler M, Macleod RA, Nagel I, Oschlies I, Rosolowski M, Russell RB, Rymkiewicz G, Schindler D, Schlesner M, Scholtysik R, Schwaenen C, Spang R, Szczepanowski M, Trümper L, Vater I, Wessendorf S, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphoma Network Project; Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group.

Blood. 2014 Feb 20;123(8):1187-98. doi: 10.1182/blood-2013-06-507996. Epub 2014 Jan 7.

18.

Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma.

Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I, d'Amore ES, Reiter A, Woessmann W, Rosolen A.

Blood. 2014 Jan 16;123(3):334-7. doi: 10.1182/blood-2013-09-526202. Epub 2013 Dec 2.

PMID:
24297868
19.

Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Abramov D, Oschlies I, Zimmermann M, Konovalov D, Damm-Welk C, Wössmann W, Klapper W.

Haematologica. 2013 Oct;98(10):1547-53. doi: 10.3324/haematol.2013.085837. Epub 2013 May 28.

20.

Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.

Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K, Reiter A, Rosolen A, Woessmann W.

Leukemia. 2013 Feb;27(2):416-22. doi: 10.1038/leu.2012.205. Epub 2012 Jul 18.

PMID:
22907048
21.

The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype.

Salaverria I, Akasaka T, Gesk S, Szczepanowski M, Burkhardt B, Harder L, Damm-Welk C, Oschlies I, Klapper W, Dyer MJ, Siebert R.

Genes Chromosomes Cancer. 2012 Apr;51(4):338-43.

PMID:
22420028
22.

Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns.

Laurent C, Lopez C, Desjobert C, Berrebi A, Damm-Welk C, Delsol G, Brousset P, Lamant L.

Leukemia. 2012 Jan;26(1):188-90. doi: 10.1038/leu.2011.209. Epub 2011 Aug 12. No abstract available.

PMID:
21836614
23.

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.

Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SN, Reiter A, Siebert R, Melnick A, Woessmann W.

PLoS One. 2011 Apr 8;6(4):e18436. doi: 10.1371/journal.pone.0018436.

24.

Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.

Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, Pulford K, Woessmann W.

Blood. 2010 Apr 22;115(16):3314-9. doi: 10.1182/blood-2009-11-251892. Epub 2010 Feb 25.

PMID:
20185586
25.

Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation.

Damm-Welk C, Klapper W, Oschlies I, Gesk S, Röttgers S, Bradtke J, Siebert R, Reiter A, Woessmann W.

Br J Haematol. 2009 Aug;146(3):306-9. doi: 10.1111/j.1365-2141.2009.07754.x. Epub 2009 May 26.

PMID:
19545284
26.

Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact.

Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, Zimmermann M, Strauch K, Ludwig WD, Schrappe M, Reiter A.

Leuk Lymphoma. 2008 Mar;49(3):451-61. doi: 10.1080/10428190701824551.

PMID:
18297521
27.
28.

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma.

Damm-Welk C, Busch K, Burkhardt B, Schieferstein J, Viehmann S, Oschlies I, Klapper W, Zimmermann M, Harbott J, Reiter A, Woessmann W.

Blood. 2007 Jul 15;110(2):670-7. Epub 2007 Mar 28.

PMID:
17392503
29.

Silencing of disease-related genes by small interfering RNAs.

Fuchs U, Damm-Welk C, Borkhardt A.

Curr Mol Med. 2004 Aug;4(5):507-17. Review.

PMID:
15267222
30.

RNA interference: new mechanisms for targeted treatment?

Woessmann W, Damm-Welk C, Fuchs U, Borkhardt A.

Rev Clin Exp Hematol. 2003 Sep;7(3):270-91. Review.

PMID:
15024970
31.

Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL).

Ritter U, Damm-Welk C, Fuchs U, Bohle RM, Borkhardt A, Woessmann W.

Oligonucleotides. 2003;13(5):365-73.

PMID:
15000827
32.

Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference.

Damm-Welk C, Fuchs U, Wössmann W, Borkhardt A.

Semin Cancer Biol. 2003 Aug;13(4):283-92. Review.

PMID:
14563123
33.

The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia.

Fuchs U, Rehkamp G, Haas OA, Slany R, Kōnig M, Bojesen S, Bohle RM, Damm-Welk C, Ludwig WD, Harbott J, Borkhardt A.

Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8756-61. Epub 2001 Jul 3.

Supplemental Content

Loading ...
Support Center